logo

Audentes Therapeutics, Inc. (BOLD)



Trade BOLD now with
  Date
  Headline
5/17/2018 7:18:00 AM Wedbush Reiterates Audentes Therapeutics, Inc. (BOLD) At Outperform With $49 Price Target
5/10/2018 9:51:57 AM Wedbush Is Increasing Audentes Therapeutics, Inc. (BOLD) FY18 Estimate To -2.98 From -3.07
5/10/2018 9:51:40 AM Wedbush Is Raising Audentes Therapeutics, Inc. (BOLD) Q4 18 Estimate To -0.76 From -0.79
5/10/2018 9:51:27 AM Wedbush Is Increasing Audentes Therapeutics, Inc. (BOLD) Q3 18 Estimate To -0.74 From -0.77
5/10/2018 9:51:15 AM Wedbush Is Raising Audentes Therapeutics, Inc. (BOLD) Q2 18 Estimate To -0.73 From -0.76
5/10/2018 9:50:44 AM Wedbush Reiterates Audentes Therapeutics, Inc. (BOLD) At Outperform With $49 Down From $56 Price Target
5/8/2018 8:02:50 AM Audentes Therapeutics Promotes Natalie Holles To President And COO
3/9/2018 8:12:04 AM Wedbush Is Increasing Audentes Therapeutics, Inc. (BOLD) FY18 Estimate To -3.07 From -3.31
3/9/2018 8:11:47 AM Wedbush Is Increasing Audentes Therapeutics, Inc. (BOLD) Q4 18 Estimate To -0.79 From -0.85
3/9/2018 8:11:35 AM Wedbush Is Increasing Audentes Therapeutics, Inc. (BOLD) Q3 18 Estimate To -0.77 From -0.83
3/9/2018 8:11:22 AM Wedbush Is Increasing Audentes Therapeutics, Inc. (BOLD) Q2 18 Estimate To -0.76 From -0.82
3/9/2018 8:11:06 AM Wedbush Is Raising Audentes Therapeutics, Inc. (BOLD) Q1 18 Estimate To -0.75 From -0.81
3/9/2018 8:10:44 AM Wedbush Reiterates Audentes Therapeutics, Inc. (BOLD) At Outperform With $56 Price Target
2/12/2018 8:15:46 AM Audentes Announces Dosing Of First Patient In VALENS, Phase 1/2 Trial Of AT342 For Treatment Of Crigler-Najjar Syndrome
2/6/2018 7:41:40 PM Audentes Therapeutics Announces Selection Of Optimized Clinical Development Candidate For Pompe Disease Program
1/24/2018 7:54:15 PM Audentes Therapeutics Announces Pricing Of Underwritten Public Offering Of 5.75 Mln Shares At $35.00/shr
1/23/2018 4:07:47 PM Audentes Therapeutics Announces Proposed Public Offering Of Common Stock